C. Costa Lopes Pinto (Lisbon, Portugal)
Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E.Author Of 1 Presentation
153P - Prevalence and survival of stage IV male breast cancer: a SEER database analysis
Abstract
Background
Male breast cancer (BC) is a rare disease, accounting for <1% of all BC cases in the United States. Delay in diagnosis can result from lack of awareness of the existence of BC among men. Since it is often late diagnosed, male BC remains a substantial cause of morbidity and mortality. The goal of this study was to evaluate the proportion of stage IV patients and their survival outcomes over time using SEER (Surveillance, Epidemiology, and End Results) data.
Methods
The data of the study was derived from SEER database. We identified patients who were male, have known age and a diagnosis between 2000-2016. We stratified year of diagnosis in 5-year categories (2001-2005; 2006-2010 and 2011-2016). Primary outcome was stage IV cancer specific survival (CSS) over time.
Results
A total of 7,339 male patients were identified. Proportion of patients with stage I-III were 79.9%, 92.0% and 91.1%, respectively by year of diagnosis category Stage IV patients accounted for 20.1%, 8.0% and 8.9%, respectively, by year of diagnosis category. The proportion of patients with stage IV at diagnosis decreased over time (p<0.001). Patterns of metastatic spread were stable over time. After a median follow-up of 50.0 months (IQR 20.0-94.0), median CSS for stage IV patients was 28.0 months (95%CI 22.3-33.7); 36.0 months (95%CI 28.47-43.5) and 33.0 months (95%CI 26.1-40.0) for the 3 consecutive time intervals (p=0.561). 5-year CSS was 21.4%, 26.8% and 15.5%, respectively.
Conclusions
Despite the reduction in stage IV diagnosis after 2005, no significant nor consistent improvement in CSS was achieved across the 3 time periods. These results raise awareness towards the need of treatment innovation uptake in the male community of metastatic breast cancer patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.